What's Going On With Tempus AI Stock Monday?

Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (RNA) test, highlighting growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease.

Ambry Genetics Hits 1Million DNA/RNA Tests Milestone

Ambry Genetics launched RNA testing commercially in 2019 as +RNAinsight. Data from over 450,000 patients showed that 1 in 25 positive patients would have been missed without RNA data. The data also showed RNA inclusion led to a 6% reduction in variants classified as uncertain.

In 2024, Ambry added RNA testing to its ExomeReveal offering for rare disease cases.

TEM’s Bearish Trend: Below SMA Indicators

Tempus AI is currently trading 11.4% below its 20-day simple moving average (SMA) and 23% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased by 2.79% over the past 12 months and are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the stock.

The RSI is at 37.98, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

• Key Resistance: $66.00
• Key Support: $59.00

TEM Earnings: Analysts’ Expectations for 2026

Investors are looking ahead to the next earnings report on Feb. 23.

• EPS Estimate: Loss of 14 cents (Up from Loss of 18 cents YoY)
• Revenue Estimate: $364.25 million (Up from $200.68 million YoY)

Analyst Consensus & Recent Actions:

The stock carries a Buy Rating with an average price target of $77.86. Recent analyst moves include:

• Canaccord Genuity: Buy (Lowers Target to $80.00) (Dec. 22, 2025)
• JP Morgan: Neutral (Lowers Target to $80.00) (Dec. 15, 2025)
• Morgan Stanley: Overweight (Raises Target to $85.00) (Dec. 2, 2025)

Tempus AI’s Benzinga Edge Scorecard Analysis

Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Weak (Score: 46.6) — Stock is underperforming the broader market.

TEM’s Premarket Price Movement Analysis

TEM Price Action: Tempus AI shares were down 1.60% at $58.86 during premarket trading on Monday, according to Benzinga Pro data.

Photo by T. Schneider via Shutterstock